APIC/CEFIC European Conference
on Active Pharmaceutical Ingredients

Objectives of the Conference

Since 20 years now, the APIC/CEFIC Conference on Active Pharmaceutical Ingredients has been Europe’s leading event. Many major stakeholders from Authorities and the Industry are each year joining this Conference. Speakers from FDA, EMA, EDQM, National Authorities, from Industry and Industry Associations will discuss the latest developments in the field of GMP and Regulatory Compliance.

The GMP Conference, of which the final part is a Joint GMP & RA session, provides updates from recent authorities’ initiatives, activities and interpretations related to GMP compliance of API manufacturing. Hear from industry speakers their approaches and best practices on compliance related to the various existing and emerging aspects of API GMP.

The conference will be opened by a presentation about Industry experiences with Quality Metrics followed by a presentation about the current status of the FDA/EMA mutual reliance initiative.. The following lectures are dedicated to Regulatory Starting Materials, the revised APIC How to do Guide on GDP for APIs, continuous processing and counterfeiting APIs.

In the Joint GMP and the Regulatory Affairs part of the conference you will get an update on EDQM’s activities and hear presentations about the ICH Q11 Q&A from a health authority perspective, the current status of ICH Q12 and its benefit from the regulator’s and industry’s perspective, the QWP’s point of view regarding ICH Q3D, API variations and generic industry’s experience, FDA’s Division of Lifecycle APIs assessment of DMFs and case studies on post approval changes.

The specific GMP and Regulatory Affairs topics to be discussed in the Parallel Sessions will relate to practical experiences with ASMF assessment/worksharing, APIC’s revised Quality Agreement Guideline and Template and practical experiences with non EU/US authorities inspections. Further topics are dedicated to data integrity issues in the analytical environment and how to prevent them, APICs experience with supporting documentation for API filings in Emerging Countries and GMP requirements for biotech vs. biological APIs.

The Parallel Sessions are no workshops. They are practically oriented and supposed to be highly interactive.